CARDIOFLOW-B (02160) gained over 4% in morning trading session. As of press time, the stock was up 4.05% to HK$1.54, with trading volume of HK$16.2265 million.

On the news front, CARDIOFLOW-B plans to hold a board meeting on August 28 to consider and approve its interim results. Previously, CARDIOFLOW-B announced that the group expects to record a net loss of no more than RMB 10 million for the first half of 2025, representing a decrease of at least 83% compared to the same period last year.

According to the announcement, the reduction in net loss was primarily attributed to: VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system has achieved sales in over 20 overseas countries/regions, with overseas revenue growing by more than double year-on-year; steady commercial progress of AnchorMan® left atrial appendage occluder system and its guiding system in China, which also obtained CE marking and achieved commercialization in Europe during the reporting period, jointly contributing to revenue growth; the group further enhanced operational efficiency through continuous optimization of resource allocation and proactive cost management; and the group's associate company 4C Medical Technologies, Inc completed Series D financing, resulting in a decrease in the group's equity stake in 4C Medical and generating deemed disposal gains on partial equity interest.